NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Haakensen, Vilde Drageset
Nowak, Anna K.
Ellingsen, Espen Basmo
Farooqi, Saima Jamil
Bjaanaes, Maria Moksnes
Horndalsveen, Henrik
Mcculloch, Tine
Grundberg, Oscar
Cedres, Susana M.
Helland, Aslaug
JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
[2] First survival data from the NIPU trial: A randomised, openlabel, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma
Helland, A.
Haakensen, V. D.
Ojlert, A. K.
Thunold, S. M. H.
Nowak, A. K.
Chin, W. L.
Grundberg, O.
Farooqi, S. J.
Lund-Iversen, M.
Szejniuk, W. M.
Perez, S. M. Cedres
Sorensen, J. B.
Bjaanaes, M. M.
ANNALS OF ONCOLOGY, 2023, 34 : S1337 - S1337
[3] Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)
Haakensen, V.
Nowak, A.
Ellingsen, E.
Grundberg, O.
Farooqi, S.
Mcculloch, T.
Cedres, S.
Bjaanaes, M.
Helland, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S380 - S380
[4] UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Haakensen, Vilde Drageset
Ojlert, Asa Kristina
Thunold, Solfrid
Farooqi, Saima
Nowak, Anna K.
Chin, Wee L.
Grundberg, Oscar
Szejniuk, Weronika Maria
Cedres, Susana
Sorensen, Jens Benn
Dalen, Tonje Sofie
Lund-Iversen, Marius
Bjaanaes, Maria
Helland, Aslaug
EUROPEAN JOURNAL OF CANCER, 2024, 202
[5] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC
Omar Kaseb, Ahmed
Duda, Dan G.
Tran Cao, Hop Sanderson
Abugabal, Yehia I.
Vence, Luis M.
Rashid, Asif
Pestana, Roberto
Blando, Jorge M.
Singh, Shalini
Vauthey, Jean-Nicolas
Hassan, Manal
Amin, Hesham M.
Qayyum, Aliya
Shin Chun, Yun
David Tzeng, Ching-Wei
Sakamuri, Divya
Wolff, Robert A.
Yao, James C.
Patrick Allison, James
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[6] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Baas, Paul
Scherpereel, Arnaud
Nowak, Anna K.
Fujimoto, Nobukazu
Peters, Solange
Tsao, Anne S.
Mansfield, Aaron S.
Popat, Sanjay
Jahan, Thierry
Antonia, Scott
Oulkhouir, Youssef
Bautista, Yolanda
Cornelissen, Robin
Greillier, Laurent
Grossi, Francesco
Kowalski, Dariusz
Rodriguez-Cid, Jeronimo
Aanur, Praveen
Oukessou, Abderrahim
Baudelet, Christine
Zalcman, Gerard
LANCET, 2021, 397 (10272): : 375 - 386
[7] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Duda, D. G.
Cao, H. S. Tran
Abugabal, Y. I.
Vence, L. M.
Rashid, A.
Pestana, R. Carmagnani
Blando, J. M.
Singh, S.
Vauthey, J. N.
Chun, Y. S.
Tzeng, C-W. D.
Sakamuri, D.
Wolff, R. A.
Yao, J. C.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30 : 880 - 880
[8] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Raghav, Kanwal Pratap Singh
Sakamuri, Divya
Girard, Lauren
Tan, Dongfeng
Vauthey, Jean-Nicolas
Tzeng, Ching-Wei David
Aloia, Thomas A.
Chun, Yun Shin
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
Disselhorst, M.
Harms, E.
Van Tinteren, H.
Quispel-Janssen, J.
Monkhorst, K.
Burgers, S.
Baas, P.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1746 - S1746
[10] Nivolumab and ipilimumab +/-UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial).
O'Day, Steven
Bechter, Oliver
Lorigan, Paul
Nyakas, Marta
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →